ACW – What's the Outlook?
Actinogen Medical (ASX:ACW) is advancing its lead candidate, Xanamem, targeting neurological conditions linked to elevated cortisol levels. The company is currently conducting the XanaMIA Phase 2b/3 trial for Alzheimer's disease, with interim results anticipated in Q3 2025 and final outcomes expected by Q4 2026 .
Recent forecasts suggest a potential short-term price range between $0.0170 and $0.0195 . While the stock has experienced a decline over the past year, the upcoming trial results could be a significant catalyst.
Given these developments, is ACW a speculative opportunity worth considering, or is it prudent to wait for more concrete data?
(20min delay)